Across TCGA pan-cancer cohorts, TMEM233 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TMEM233 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher TMEM233 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TMEM233 expression acts as an unfavorable survival marker.

BRCA, COAD, and SARC are the cancer types where TMEM233 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.073	0.964	<.001	36	view →
COAD	OS	Median	II,III,IV	0.001	0.851	<.001	11	view →
SARC	OS	Median	All	0.127	0.860	<.001	9	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: TMEM233 tumor-vs-normal RNA expression · all TMEM233 data types